Patents Examined by Robert A. Zeman
  • Translocation and mutant ROS kinase in human non-small cell lung carcinoma
    Patent number: 10889818
    Abstract: In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: January 12, 2021
    Assignee: CELL SIGNALING TECHNOLOGY, INC.
    Inventors: Ailan Guo, Anthony Possemato
  • Method for treating pancreatic cancer with vaccine
    Patent number: 10864258
    Abstract: Attenuated Toxoplasma gondii mutants and methods using the same as vaccines in the prevention or treatment pancreatic cancer are provided.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: December 15, 2020
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: David J. Bzik, Barbara A. Fox, Kiah L. Sanders
  • Pet food compositions including probiotics and methods of manufacture and use thereof
    Patent number: 10849338
    Abstract: The present invention encompasses pet food compositions that include one or more probiotic microorganisms, which are useful to improve the health of companion animals. For example, the invention encompasses pet food compositions including a probiotic, for example, Lactobacillus, Bifidobacterium and Streptococcus (Enterococcus). The present invention also encompasses the preparation of pet food compositions including one or more probiotic microorganisms intended for methods of maintaining or improving pet health through feeding a pet a pet food composition including the probiotic microorganism.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: December 1, 2020
    Assignee: Hills Pet Nutrition, Inc.
    Inventors: Pavinee Chinachoti, Kathy Gross, Christina Khoo, Luis Montelongo
  • O-linked glycoforms of polypeptides and method to manufacture them
    Patent number: 10844110
    Abstract: The present invention relates to compositions comprising glycoproteins having altered patterns of O-linked glycosylation, in particular Factor VII, Factor IX, and methods for making these.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: November 24, 2020
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Niels Kristian Klausen, Daniel E. Rasmussen
  • Type III secretion injectisome proteins for treatment and prevention of chlamydial infections
    Patent number: 10835594
    Abstract: Cpn0803, CopB (Cpn0809) and CopD (Cpn0808) proteins and homologues thereof are shown to induce an immune response that is protective against a live challenge with Chlamydia. Methods and uses of Cpn0803 or fragments or epitopes thereof alone or together with CopB and/or CopD or fragments or epitopes thereof for treating or preventing chlamydial infection in a subject in need thereof are provided.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: November 17, 2020
    Assignee: McMaster University
    Inventors: James B. Mahony, David C. Bulir, Christopher B. Stone
  • Monoclonal antibody inhibiting immunosuppressive functions of pathogens, antigen-binding fragment thereof, and hybridomas producing such antibody
    Patent number: 10808025
    Abstract: The present invention relates to a monoclonal antibody that inhibits immunosuppressive functions of pathogens, antigen-binding fragment thereof, and hybridomas producing such antibody. The monoclonal antibody or antigen-binding fragment thereof bind to a peptide consisting an amino acid sequence represented by MEKVGKDGVITVE (SEQ ID NO: 1). The present invention also discloses use of the invented monoclonal antibody or antigen-binding fragment thereof, and method of preparation for such hybridomas.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: October 20, 2020
    Assignee: SAGABIO CO., LTD.
    Inventors: Kuang-Wen Liao, Yu-Ling Lin, Ting-Yan Jian
  • Immunotherapies employing self-assembling vaccines
    Patent number: 10800837
    Abstract: Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: October 13, 2020
    Assignee: The General Hospital Corporation
    Inventors: Jeffrey A. Gelfand, Mark C. Poznansky, Pierre R. Leblanc, Svetlana E. Korochkina
  • Consensus antigen constructs and vaccines made therefrom, and methods of using the same to treat malaria
    Patent number: 10799572
    Abstract: Provided herein is consensus amino acid sequences of P. falciparum (P.f.) proteins and their encoding sequences, as well as expression constructs expressing the sequences. Also provided herein are methods for generating an immune response against P. falciparum using the expression constructs provided herein.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: October 13, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Bernadette Ferraro, Jian Yan, Niranjan Y. Sardesai
  • Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
    Patent number: 10786555
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: September 29, 2020
    Assignee: Applied Molecular Transport Inc.
    Inventors: Randall J. Mrsny, Tahir Mahmood
  • Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
    Patent number: 10786556
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: September 29, 2020
    Assignee: Applied Molecular Transport Inc.
    Inventors: Randall J. Mrsny, Tahir Mahmood
  • Vaccine compositions and methods
    Patent number: 10751372
    Abstract: The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceutical compositions to prevent or treat diseases, such as cancer, infectious diseases and autoimmune disease are also included.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: August 25, 2020
    Assignee: MIRROR BIOLOGICS, INC.
    Inventor: Michael Har-Noy
  • Anti-inflammatory compounds and methods of use
    Patent number: 10752662
    Abstract: Methods of treating or inhibiting inflammation in a subject include administering an anti-inflammatory protein to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 17, or fragments thereof. Isolated polypeptides, nucleic acids, and recombinant vectors including a nucleic acid encoding the anti-inflammatory protein (such as a nucleic acid encoding a protein with at least 80% sequence identity to SEQ ID NO: 1, SEQ ID NO: 17, or fragments thereof) operably linked to a heterologous promoter are also disclosed.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: August 25, 2020
    Assignee: University of Oregon
    Inventors: Karen Guillemin, Annah Rolig, Emily Sweeney
  • Immunoglobulin Fc libraries
    Patent number: 10725037
    Abstract: Methods and composition for the screening and isolation of aglycosylated antibody Fc domain polypeptides. For example, in certain aspects methods for identifying aglycosylated Fc domains that bind to Fc receptors or preferentially bind to particular Fc receptors are described. Furthermore, the invention provides aglycosylated Fc domains that bind to Fc receptors with high affinity. Enhanced methods and media for prokaryotic based interaction screening are also provided.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: July 28, 2020
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Sang Taek Jung
  • Aquaporin 2 protects cattle from ticks and tick-borne parasites
    Patent number: 10722561
    Abstract: A novel method of using an aquaporin protein from Rhipicephalus microplus (RmAQP2), fragments of RmAQP2, and/or the cDNA encoding RmAQP2 and/or the fragments are described. Immunogenic composition containing recombinant RmAQP2 and/or fragments of RmAQP2 are produced and administered to an ungulate which generates an immune response to RmAQP2. After feeding female ticks on the ungulate injected with RmAQP2 and/or fragments of RmAQP2, the female ticks have lower reproductive viability because of a reduced egg mass, reduced hatching percentage, and reduced survival of larvae. Thus, administering RmAQP2 and/or RmAQP2 fragments to an ungulate can reduce the incidence of R. microplus and also reduce the incidence of tick-borne pathogens in ungulates because of the lower number of R. microplus.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: July 28, 2020
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Glen A. Scoles, Felicito Guerrero, Reginaldo Bastos
  • Increasing lipid production and optimizing lipid composition
    Patent number: 10724041
    Abstract: Disclosed are nucleotide sequences and corresponding amino acid sequences of Arxula adeninivorans genes that can be utilized to manipulate the lipid content and/or composition of a cell. Methods and compositions for utilizing this information are disclosed to increase the lipid content or modify the lipid composition of a cell by either increasing or decreasing the activity of certain genetic targets.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: July 28, 2020
    Assignee: NOVOGY, INC.
    Inventors: Elena E. Brevnova, Arthur J. Shaw, IV, Johannes P. Van Dijken
  • Biosensor
    Patent number: 10712341
    Abstract: Biosensors are made by attaching covalently or non-covalently at least one reporter group to one or more specific positions of a bacterial periplasmic binding protein (bPBP). Upon binding of ligand to the biosensor, there is a change in the signal transduced by the reporter group.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 14, 2020
    Assignee: Duke University
    Inventors: Homme W. Hellinga, Loren L. Looger
  • Metalloproteases
    Patent number: 10696958
    Abstract: Aspects of the present compositions and methods relate to novel metalloproteases, polynucleotides encoding the novel metalloproteases, and compositions and methods for use thereof.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: June 30, 2020
    Assignee: DANISCO US INC
    Inventors: Lilia M. Babe, Frits Goedegebuur, Roopa Ghirnikar, Xiaogang Gu, Marc Kolkman, Jian Yao
  • Multiepitope fusion antigens and vaccines and their use in treatment of enterotoxigenic diarrhea
    Patent number: 10646560
    Abstract: Provided herein are polypeptides comprising up to 9 antigenic elements of ETEC virulence determinants: 7 CFA adhesins [CFA/I, CFA/II (CS1, CS2, CS3), CFA/IV (CS4, CS5, CS6)] expressed by the most prevalent and virulent ETEC strains, and 2 toxins expressed by all ETEC strains, were genetically fused together for CFA-toxoid fusion with proteins (CFA/I/II/IV-STa-toxoidLTtoxoid). Methods for making these polypeptides and their use in the treatment of ETEC related disease are also provided.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: May 12, 2020
    Assignees: The John Hopkins University, South Dakota State University
    Inventors: David A. Sack, Weiping Zhang
  • Rapid analysis for cyanobacterial toxins
    Patent number: 10641769
    Abstract: Method and compositions using transition metal salts and/or ammonium chloride to liberate toxins and other molecules from cyanobacteria, useful for assaying for total cyanobacterial toxins in lakes, reservoirs and other waters.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: May 5, 2020
    Assignee: Abraxis, Inc.
    Inventors: Fernando Manuel Rubio, Lisa Marie Kamp
  • Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
    Patent number: 10624956
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: April 21, 2020
    Assignee: Applied Molecular Transport Inc.
    Inventors: Randall J. Mrsny, Tahir Mahmood